ArticleFrontiers in public health2025
An analysis of cost-saving in the German statutory health insurance system due to the introduction of epoetin alfa biosimilars in Germany.
Article in Frontiers in public health, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Aims: Epoetin alfa, an erythropoiesis-stimulating agent, is the mainstay for treating severe anemia caused by kidney disease or induced by cancer-chemotherapy. This study aims to investigate the potential for reducing drug costs through the utilization of epoetin alfa biosimilars within the German statutory health insurance system (SHI). Methods: For the analysis, price and product data from ABDATA with sales volume data from IQVIA Pharmascope for the period from 2008 to 2023 were pooled. This enabled a comparison of cost savings due to the market introduction of epoetin alfa biosimilars from 2007 onwards. Results: From 2008 to 2023, overall epoetin alfa unit volume has increased by a total of 23%. Compared to the other epoetin derivatives such as, epoetin beta, zeta and theta, an average unit share of 57% (between 2008 and 2023) highlights the importance of epoetin alfa within the segment of erythropoiesis-stimulating agents. Among the various dosing strengths of epoetin alfa, the nephrological strength 4,000 IU formulation has gained notable sales growth (12%) from 2008 to 2023. Economically, the introduction of epoetin alfa biosimilars has led to substantial cost-savings for the SHI, amounting to €505,731,202 between 2008 and 2023 for nephrological strengths. Due to biosimilar competition, the price of epoetin alfa decreased by 47% from 2007 to 2012, further contributing to the diminished price difference between originator epoetin and other epoetin alfa biosimilars. Notably, the 4,000 IU nephrological strength alone accounted for savings of €143,720,363, reflecting its widespread clinical adoption. Conclusion: The introduction of epoetin alfa biosimilars has not only enhanced clinical accessibility, but also yielded significant cost savings for the German healthcare system. This underscores the dual role of biosimilars in improving healthcare affordability and maintaining effective therapeutic outcomes.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.